Rossella LibÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8560889/publications.pdf

Version: 2024-02-01

33 papers	2,638 citations	430874 18 h-index	414414 32 g-index
36 all docs	36 docs citations	36 times ranked	2991 citing authors

#	Article	IF	Citations
1	Recurrence of a Pheochromocytoma With TNEM127 Mutation Negative on 18F-FDOPA and 18F-FDG but Positive on 123I-MIBG and 68Ga-DOTATOC Imaging. Clinical Nuclear Medicine, 2022, 47, 251-252.	1.3	0
2	KDM1A inactivation causes hereditary food-dependent Cushing syndrome. Genetics in Medicine, 2022, 24, 374-383.	2.4	27
3	Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2167-e2176.	3.6	3
4	A pheochromocytoma wrapped in an IgG4-related disease. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 929-930.	6.4	0
5	Preoperative Detection of Liver Involvement by Right-Sided Adrenocortical Carcinoma Using CT and MRI. Cancers, 2021, 13, 1603.	3.7	3
6	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of Personalized Medicine, 2021, 11, 269.	2.5	14
7	Letter to the Editor from Berthon: â€œCardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patient With Cortisol-Secreting Adrenocortical Adenomaâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4183-e4184.	3.6	1
8	An Ectopic Parathyroid Adenoma Mimicking a Carotid Body Paraganglioma. Journal of the Endocrine Society, 2020, 4, bvaa143.	0.2	1
9	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2367-2374.	3.6	103
10	18F-FDG PET reveals an adrenocortical carcinoma in a bilateral adrenal multinodular disease. Endocrine, 2019, 63, 188-189.	2.3	4
11	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. European Journal of Endocrinology, 2019, 180, 311-320.	3.7	16
12	MiRâ€483â€5p and miRâ€139â€5p promote aggressiveness by targeting Nâ€myc downstreamâ€regulated gene family members in adrenocortical cancer. International Journal of Cancer, 2018, 143, 944-957.	5.1	51
13	Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors. Hormones and Cancer, 2018, 9, 62-69.	4.9	18
14	Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation. Modern Pathology, 2018, 31, 1708-1716.	5.5	29
15	Clinical and molecular prognostic factors in adrenocortical carcinoma. Minerva Endocrinologica, 2018, 44, 58-69.	1.8	12
16	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	3.6	33
17	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3205.	3.6	44
18	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	16.8	482

#	Article	IF	Citations
19	Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Frontiers in Cell and Developmental Biology, 2015, 3, 45.	3.7	151
20	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6044.	12.8	153
21	Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. European Journal of Endocrinology, 2014, 170, 385-391.	3.7	37
22	A Feminizing Adrenocortical Carcinoma in the Context of a Late Onset 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1943-1944.	3.6	9
23	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	21.4	560
24	Rasch analysis for assessing unidimensionality and identifying measurement biases of malignancy scores in oncology. The example of the Weiss histopathological system for the diagnosis of adrenocortical cancer. Cancer Epidemiology, 2014, 38, 200-208.	1.9	4
25	Adrenocortical Tumors. American Journal of Surgical Pathology, 2012, 36, 1194-1201.	3.7	47
26	A Rare Cause of Hypertestosteronemia in a 68â€Yearâ€Old Patient: A Leydig Cell Tumor Due to a Somatic GNAS (Guanine Nucleotideâ€Binding Protein, Alphaâ€Stimulating Activity Polypeptide) Tj ETQq0 0 0 rgBT /Overlock10 Tf 50	2.0	18
27	Î²-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma. Clinical Cancer Research, 2011, 17, 328-336.	7.0	128
28	Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. European Journal of Endocrinology, 2010, 163, 129-138.	3.7	89
29	Transcriptome Analysis Reveals that p53 and Î²-Catenin Alterations Occur in a Group of Aggressive Adrenocortical Cancers. Cancer Research, 2010, 70, 8276-8281.	0.9	134
30	Adrenocortical Tumor with Two Distinct Elements Revealed by Combined 18F-Fluorodeoxyglucose Positron Emission Tomography and 131I Nor-Cholesterol Scintigraphy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3631-3632.	3.6	6
31	18F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Adrenocortical Tumors: A Prospective Study in 77 Operated Patients. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1713-1722.	3.6	195
32	Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity. Clinical Cancer Research, 2007, 13, 844-850.	7.0	104
33	Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. European Journal of Endocrinology, 2005, 153, 477-487.	3.7	158